Arbutus Biopharma Corp
ABUS
Get informed when a big investor buys or sells
+ FollowMarket Cap$922.5M
Close$
$-3.05
163.1% downside
Current Fair Value
163.1% downsideOvervalued by 163.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $922.50 Million |
|---|---|
| Enterprise Value | $903.84 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.17 |
| Beta | 0.6 |
| Outstanding Shares | 197,470,724 |
Return
| Return on Equity | 59.16% |
|---|---|
| Return on Assets | 55.85% |
| Return on Invested Capital | 54.56% |
Valuation & Multiples
| P/E Ratio | 5.91 |
|---|---|
| PEG | -1.94 |
| Price to Sales | - |
| Price to Book Ratio | 4.84 |
| Enterprise Value to Revenue | 4.97 |
| Enterprise Value to EBIT | 6.12 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$700,000
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$1.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9502▼ 13.94% |
|---|---|
| Total Calls | 186,600▼ 60.32% |
| Total Puts | 177,300▼ 65.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 72.31%▲ 0.58% |
|---|---|
| Total Invested | $672.43M▲ 7.52% |
| Investors Holding | 179▲ 4.00% |
ESG Score
No data
About Arbutus Biopharma Corp
CEO: William Collier